Angion Biomedica Corp

+0.14 (+1.30%)
Products, Regulatory, Other Pre-Announcement

Angion Announces Results From The Phase 2 Ali-201 Study In Patients With Covid-19 Associated Pneumonia

Published: 06/29/2021 20:57 GMT
Angion Biomedica Corp (ANGN) - Angion Announces Results From the Phase 2 Ali-201 Study in Patients With Covid-19 Associated Pneumonia.
Angion Biomedica - Exploratory Phase 2 Ali-201 Trial of Ang-3777 Did Not Meet Primary Or Secondary Efficacy Endpoints.
Angion Biomedica - Adverse Events, Overall Safety of Trial Consistent With Previously Published Reports in Patients Hospitalized With Severe Covid-19 Pneumonia.
Angion Biomedica Corp - Will Continue to Evaluate Clinical Development of Ang-3777 for Acute Lung Injury Populations.
Angion Biomedica - None of Fatal Events in Trial of Advanced Covid-19 Patients Attributed by Study Investigators to Ang-3777 Or Standard of Care in Control Arm.
Angion Biomedica - Expects to Report Data From Ang-3777 Phase 3 Registration Trial in Transplant-associated Acute Kidney Injury by End of 2021.